Marengo's Phase II trial is assessing T cell activator invikafusp alfa in the treatment of advanced PD-1 resistant solid tumours.

Both trials recruited patients with psoriatic arthritis who had not previously received biologic disease-modifying antirheumatic drugs.

AI continued to be shown as an invaluable tool with the potential to accelerate clinical trials and improve patient care.

The Phase III trial is set to use growth outcomes as its primary endpoint in the 52-week trial of JR-142, a long-acting growth hormone.